Treatment of Rosacea

Introduction

• Rosacea is a chronic skin condition that requires ongoing treatment and patient education to manage symptoms and prevent relapse, as recommended by the American Academy of Dermatology and the British Journal of Dermatology 1, 2

Pharmacological Interventions

• Topical metronidazole 0.75% or 1% is the preferred first-line treatment for rosacea during pregnancy, with a success rate of 30% in non-pregnant patients, although the efficacy in pregnant women is not well established, as supported by the American College of Obstetricians and Gynecologists 1
• Azelaic acid is another topical option with a better safety profile during pregnancy compared to ivermectin, and can be added to topical metronidazole for inadequate response, as recommended by the British Journal of Dermatology 1
• For moderate to severe papulopustular rosacea that has not responded to topical treatments, oral doxycycline is recommended, as supported by the American Academy of Dermatology and the British Journal of Dermatology 1, 2
• The combination of oral doxycycline and topical azelaic acid is an effective treatment strategy for patients with rosacea, with significant reduction in inflammatory lesions evident by 3 weeks, and continued improvement through 12-16 weeks, as recommended by the American Academy of Dermatology and the British Journal of Dermatology 1, 2
• The recommended topical agent to use in combination with oral doxycycline is 15% azelaic acid gel/foam, which possesses antimicrobial activity against P. acnes and S. epidermidis, normalizes keratinization, and has anticomedonal effects, with a success rate of 51-58% reduction in inflammatory lesions and 44-46% improvement in erythema, as recommended by the American Academy of Dermatology and the British Journal of Dermatology 1, 2
• Ivermectin 1% cream has a success rate of 38.4-40.1% in large clinical trials, but is not recommended during pregnancy due to unknown risks, as supported by the CDC guidelines 1, 3
• Encapsulated benzoyl peroxide 5% (E-BPO 5%) cream has a rapid onset of action, as recommended by the American Academy of Dermatology 1
• The following table summarizes the efficacy of different treatments:

Ocular Rosacea Treatment

• Lid hygiene, including daily cleansing of eyelid margins, warm compresses, and eyelid massage to express meibomian glands, is a recommended first-line treatment for ocular rosacea, as recommended by the British Journal of Dermatology 2
• Artificial tears, particularly preservative-free formulations, are recommended for mild ocular burning/stinging, as recommended by the British Journal of Dermatology 2
• Topical antimicrobials, oral antibiotics, cyclosporine ophthalmic emulsion, and intense pulsed light (IPL) therapy are effective treatment options for ocular rosacea, as recommended by the British Journal of Dermatology 2
• Systemic ivermectin has demonstrated efficacy in reducing Demodex folliculorum in patients with ocular rosacea, according to the American Academy of Ophthalmology 4, 5

Pediatric Rosacea Treatment

• Mild cases of pediatric rosacea can be managed with gentle skincare, sun protection (SPF 30+), and topical metronidazole 0.75% or 1% once daily, with reassessment after 3-4 weeks, as recommended by the American Academy of Dermatology 1
• Moderate cases of pediatric rosacea may require topical metronidazole twice daily, and consideration of adding azelaic acid if response is inadequate, with oral antibiotics considered for children ≥8 years if there is an inadequate response to topicals, as suggested by the American Academy of Dermatology and the British Journal of Dermatology 1, 2

Laser Therapy

• Pulsed-dye laser (PDL) and intense pulsed light (IPL) are equally effective first-line laser options for treating erythema and telangiectasia, with the choice depending on the specific rosacea phenotype, as recommended by the British Journal of Dermatology 2
• Typically, 3-4 treatment sessions at 3-4 week intervals are required for optimal results, although the specific protocol may vary depending on the individual patient's needs, as recommended by the British Journal of Dermatology 2

Treatment Evaluation and Adherence

• Evaluate response at 3-4 week intervals initially, and allow sufficient time (6-12 weeks) before considering treatment failure, with consideration of adjusting treatment approach if minimal improvement after 6-8 weeks, as recommended by the British Journal of Dermatology 1, 2
• Patient adherence to treatment regimen is crucial for effective treatment, with up to 89% of patients experiencing adverse effects discontinuing therapy within a month, highlighting the importance of selecting treatments with favorable tolerability profiles, as supported by the American Academy of Dermatology and the British Journal of Dermatology 1, 2